HotSpot Therapeutics Unveils Promising New IRF5 Inhibitor Data at European Lupus Meeting HotSpot Therapeutics recently shared exciting preclinical data for their new IRF5 inhibitor, showcasing its potential in treating autoimmune diseases at the European Lupus Meeting.

HotSpot Therapeutics Unveils Promising New IRF5 Inhibitor Data at European Lupus Meeting #United_States #Boston #Autoimmune_Diseases #HotSpot_Therapeutics #IRF5_Inhibitor

HotSpot Therapeutics Unveils Cutting-Edge Research at European Lupus Meeting HotSpot Therapeutics is set to showcase groundbreaking preclinical findings on IRF5 inhibitors at the 15th European Lupus Meeting in Lisbon.

HotSpot Therapeutics Unveils Cutting-Edge Research at European Lupus Meeting #Portugal #Lisbon #Lupus_Research #HotSpot_Therapeutics #IRF5_Inhibitor

HotSpot Therapeutics Shares Promising Results from Innovative Cancer Therapy at ESMO 2025 HotSpot Therapeutics unveiled groundbreaking preclinical data on its CBM signalosome inhibitors, heralding a new era in treating KRAS-driven cancers at ESMO 2025.

HotSpot Therapeutics Shares Promising Results from Innovative Cancer Therapy at ESMO 2025 #USA #cancer_therapy #Boston #HotSpot_Therapeutics #CBM_signalosome

HotSpot Therapeutics to Unveil Preclinical Findings of CBM Inhibitors at ESMO Gastrointestinal Congress 2025 HotSpot Therapeutics is set to present crucial preclinical data on its CBM signalosome inhibitor program at the ESMO Gastrointestinal Cancers Congress 2025, sharing insights from two significant poster sessions in Barcelona.

HotSpot Therapeutics to Unveil Preclinical Findings of CBM Inhibitors at ESMO Gastrointestinal Congress 2025 #Spain #Barcelona #Colorectal_Cancer #HotSpot_Therapeutics #CBM_signalosome

HotSpot Therapeutics Reveals Groundbreaking Preclinical Data on IRF5 Inhibition at FOCIS 2025 HotSpot Therapeutics has presented innovative preclinical results for their IRF5 program at FOCIS 2025, showcasing potential for autoimmune disease treatments.

HotSpot Therapeutics Reveals Groundbreaking Preclinical Data on IRF5 Inhibition at FOCIS 2025 #United_States #Boston #HotSpot_Therapeutics #IRF5_inhibitors #Smart_Allostery

HotSpot Therapeutics Set to Unveil Promising IRF5 Data at FOCIS 2025 in Boston HotSpot Therapeutics will showcase preclinical findings from its IRF5 program at FOCIS 2025, emphasizing innovative drug discovery targeting autoimmune diseases.

HotSpot Therapeutics Set to Unveil Promising IRF5 Data at FOCIS 2025 in Boston #USA #Boston #HotSpot_Therapeutics #IRF5_Program #FOCIS_2025